Medtronic acquires Heartware International

Medtronic to Expand Heart Failure Portfolio with Acquisition of Heartware International

Medtronic plc

Extends Clinical and Commercial Leadership Into
Growing Circulatory Support Sector

DUBLIN and FRAMINGHAM, Mass. – June 27, 2016 – Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic’s second fiscal quarter ending Oct. 28, 2016, subject to the satisfaction of customary closing conditions.

Medtronic’s acquisition of HeartWare will expand Medtronic’s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic’s Mission of alleviating pain, restoring health and extending life, and is in line with the Company’s strategy to surround the physician with innovative products while focusing on patients and disease states.

HeartWare’s flagship product, the HVAD® System, features the world’s smallest full-support ventricular assist device (VAD) and is designed to reduce surgical invasiveness, improve patient recovery times and enhance patient outcomes. In addition, HeartWare has multiple technologies in development designed to offer progressively less-invasive mechanical circulatory support options for patients with end-stage heart failure. Medtronic estimates that the global VAD market is approximately $800 million currently and worldwide is expected to grow in the mid-to-high single digits for CY16-17, and accelerate to high-single/low-double digits beyond CY17.
See this link:
http://ir.heartware.com/phoenix.zhtml?c=187755&p=irol-newsarticle&ID=2196863

Written by

Ita-Sono Francesco e gestisco questo sito con notizie relative alle mie esperienze lavorative. Sono perito industriale in Energia Nucleare. Ho iniziato a lavorare in questo campo di eccellenza scientifica molti anni fa. La polivalenza di questa disciplina scientifica mi ha sempre permesso di affrontare con solide basi tecniche molti problemi nei più diversi settori industriali. Il passaggio dal Nucleare al Biomedicale fu a suo tempo quasi naturale attraverso lo studio e lo sviluppo delle prime batterie nucleari a conversione termoelettrica dell'energia. Questa applicazione era dettata dalle esigenze di lunga durata dell'alimentazione dei primi Pace-maker impiantabili. **eng-My name is Francesco and I manage this site with news related to my work experience. I'm an industrial expert in Nuclear Energy. I started working in this field of scientific excellence many years ago. The versatility of this scientific discipline has always allowed me to deal with solid technical foundations many problems in various industrial sectors. The transition from the Nuclear Biomedical was almost natural to its time through the study and development of the first nuclear batteries in thermoelectric energy conversion. This application was dictated by the needs of long-term supply of the first implantable pacemakers.